Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors.
Bombardieri
E
E
Nuclear Medicine Division, Italian Trials of Medical Oncology, National Cancer Institute, Milan, Italy. bombardieri@istitutotumori.mi.it
Seregni
E
E
Savelli
G
G
Villano
C
C
Castellani
M R
MR
Cirillo
F
F
Pallotti
F
F
Fracassi
S
S
Chiesa
C
C
Chiti
A
A
Bajetta
E
E
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D007205:Indium Radioisotopes / Q000627:therapeutic use*; D007558:Italy; D008297:Male; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011829:Radiation Dosage; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D013004:Somatostatin; C081788:pentetreotide